Low-Dose Abiraterone a Rare European Commodity

摘要

An article by Patel et al titled “Low-Dose Abiraterone in Metastatic Prostate Cancer: Is it Practice Changing? Facts and Facets” was published in on March 3, 2020. We concur with the findings of Patel et al, as do other commentators, that use of a low-dose strategy using 250 mg of abiraterone compared with 1000 mg leads to significant cost savings and will improve access for patients.